PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
11954048-0	2002	Differential regulation of GAD67, enkephalin and dynorphin mRNAs by chronic-intermittent L-dopa and A2A receptor blockade plus L-dopa in dopamine-denervated rats.	Levodopa	89-95	proenkephalin	Rattus norvegicus	34-44	
11954048-6	2002	Chronic-intermittent L-dopa (6 mg/kg) treatment increased the striatal levels of GAD67, dynorphin, and enkephalin mRNA in the lesioned side as compared to the vehicle treatment.	Levodopa	21-27	proenkephalin	Rattus norvegicus	103-113	
11954048-0	2002	Differential regulation of GAD67, enkephalin and dynorphin mRNAs by chronic-intermittent L-dopa and A2A receptor blockade plus L-dopa in dopamine-denervated rats.	Levodopa	127-133	proenkephalin	Rattus norvegicus	34-44	
3792452-3	1986	Administration of L-DOPA plus carbidopa, bromocriptine or pergolide for 12 months decreased [Met5]enkephalin (except bromocriptine) and neurotensin, but not [Leu5]enkephalin, levels in striatum.	Levodopa	18-24	proenkephalin	Rattus norvegicus	98-108	
1385171-4	1992	Administration of L-DOPA to sham-operated rats bilaterally increased SP levels in striatum and substantia nigra, and [Met5]enkephalin and CCK content in substantia nigra.	Levodopa	18-24	proenkephalin	Rattus norvegicus	123-133	
1385171-5	1992	L-DOPA treatment of 6-OHDA-lesioned rats increased [Met5]- and [Leu5]enkephalin and CCK levels in the striatum ipsilateral to the lesion but not on the intact side.	Levodopa	0-6	proenkephalin	Rattus norvegicus	69-79	
1385171-6	1992	In the substantia nigra, the lesion-induced decrease in [Leu5]enkephalin and SP was reversed by L-DOPA treatment, [Met5]enkephalin and CCK levels ipsilateral to the lesion were further enhanced, and there was an increase in NT ipsilateral to the lesion.	Levodopa	96-102	proenkephalin	Rattus norvegicus	62-72	
1717109-6	1991	In contrast, continuous levodopa elevated globus pallidus enkephalin beyond the levels occurring with denervation, but had no effect on any of the other neurochemical measures.	Levodopa	24-32	proenkephalin	Rattus norvegicus	58-68	
1717109-8	1991	With the exception of substance P, levodopa did not reverse the effects of the 6-OHDA lesion but, rather, either exacerbated the lesion-induced changes (e.g. GAD and enkephalin) or altered neurochemical markers which had been unaffected by the lesion (e.g. CAT and dynorphin).	Levodopa	35-43	proenkephalin	Rattus norvegicus	166-176	
9221930-6	1997	Topographical analysis revealed that long-term L-DOPA treatment reversed, in fact, both post-lesional enkephalin and substance P responses to 6-hydroxydopamine lesion, in the ventromedial neostriatum, without significantly modified these peptide responses in the dorsolateral neostriatum.	Levodopa	47-53	proenkephalin	Rattus norvegicus	102-112	
7637869-5	1995	The effect of L-DOPA on the gene expression of preproenkephalin and glutamate decarboxylase (M(r) 67,000) differs from the increase in striatal enkephalin content and glutamate decarboxylase activity previously found following L-DOPA treatment.	Levodopa	14-20	proenkephalin	Rattus norvegicus	53-63	
7637869-5	1995	The effect of L-DOPA on the gene expression of preproenkephalin and glutamate decarboxylase (M(r) 67,000) differs from the increase in striatal enkephalin content and glutamate decarboxylase activity previously found following L-DOPA treatment.	Levodopa	227-233	proenkephalin	Rattus norvegicus	53-63	
27072528-0	2016	Enkephalin and dynorphin neuropeptides are differently correlated with locomotor hypersensitivity and levodopa-induced dyskinesia in parkinsonian rats.	Levodopa	102-110	proenkephalin	Rattus norvegicus	0-10	
29452071-13	2018	Moreover, KN-93 treatment reduced the expression of Arc and Penk, two immediate early genes, induced by chronic L-dopa.	Levodopa	112-118	proenkephalin	Rattus norvegicus	60-64	
14622157-7	2003	L-DOPA produced a high and similar increase in GAD67 mRNA in enkephalin (-) and (+) neurons.	Levodopa	0-6	proenkephalin	Rattus norvegicus	61-71	
23185117-19	2012	CONCLUSION: These data indicated that levodopa/benserazide-loaded microspheres could be used to ameliorate the expression of LID by reducing the expression of pGluR1S831 and pGluR1S845 as well as Arc and Penk.	Levodopa	38-46	proenkephalin	Rattus norvegicus	204-208	
14663008-4	2003	The expression of dynorphin and, to a lesser extent, enkephalin mRNAs was increased in the lesioned striatum of rats that received long-term L-dopa treatment but not in rats that received long-term SCH 58261 + L-dopa treatment.	Levodopa	141-147	proenkephalin	Rattus norvegicus	53-63	
20456008-9	2010	Chronic IEM 1460 treatment reversed L-DOPA-induced up-regulation of pre-proenkephalin-A, and normalised pre-proenkephalin-B mRNA expression in the lateral striatum, indicating an inhibition of both behavioural and molecular correlates of priming.	Levodopa	36-42	proenkephalin	Rattus norvegicus	72-87	
19118628-6	2009	Additionally, L-DOPA-induced elevations in striatal pre-proenkephalin-A (PPE-A) (but not PPE-B, phospho[Thr(34)]DARPP-32, D1, and D2 receptor mRNA or D3 receptor levels) were reduced in S33084 treated animals.	Levodopa	14-20	proenkephalin	Rattus norvegicus	56-71